/

Empresas

Ky

No verificado

Kyowa Kirin International

Sobre qué escribimos

CienciaFarmacéuticaIndustriaMedicina - VariosSalud

3 Comunicados de prensa

Ver todos los comunicados de prensa

22/10/2025

Industria

Salud

Sanidad

Ciencia

Medicina - Varios

Farmacéutica

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)

Fuente

Kyowa Kirin International

Editor

1.00

0

30/01/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

Fuente

Kyowa Kirin International

Editor

1.00

0

01/10/2024

Eventos

Ferias y Congresos

Industria

Salud

Ciencia

Farmacéutica

Medicina - Varios

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

Fuente

Kyowa Kirin International

Editor

1.00

0

Seguidores

0

Compatibilidad

0